Adrian Dillon is resigning from his position as executive vice president (EVP), finance and administration, and chief financial officer at Agilent Technologies, effective April 1.
Following Dillon’s resignation, Didier Hirsch, currently VP, corporate controllership and tax, will become acting chief financial officer. Hirsch has worked at Agilent since it formed. Before this he held various positions at Hewlett-Packard.
iBio has named Vidadi Yusibov as chief scientific officer. Yusibov is executive director of the Fraunhofer USA Center for Molecular Biotechnology (CMB) in Newark, Delaware, a role he will continue after joining iBio.
UK-based Q Chip, a biotech developing sustained release formulations, has appointed Tony Mills to its board of directors. Mills has more than 20 years experience in biotech commercialisation at companies including Peptide Therapeutics, BioVex and Phynova.
VGXI has made three appointments. Firstly, David Weiner has joined the company’s scientific advisory board. Weiner is chairman of Inovio Biomedical’s scientific advisory board and professor of pathology and laboratory medicine at the University of Pennsylvania, US.
Also, Sandra Jones has been named as director of validation and David Colvin has been appointed as key account manager. Jones joins from Beckman-Coulter and Colvin from Merck & Co.
Yehong Zhang has been named as president of Simcere Pharmaceutical Group. Zhang has 18 years in the healthcare industry at companies including Merck & Co, McKinsey and IMS.
Sanofi Aventis has nominated Catherine Brechignac to its board of directors. Shareholders will be asked to approve Brechignac’s appointment in May. If approved, Brechignac will replace Jean-Marc Bruel who is not seeking reappointment to the board.